<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00099853</url>
  </required_header>
  <id_info>
    <org_study_id>CLAF237A2304</org_study_id>
    <nct_id>NCT00099853</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes</brief_title>
  <official_title>Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a&#xD;
      single oral drug. The purpose of this study is to assess the safety and effectiveness of&#xD;
      vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to&#xD;
      pioglitazone in people with type 2 diabetes not at target blood glucose levels on either&#xD;
      pioglitazone or rosiglitazone alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c after 24 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting plasma glucose at 24 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with endpoint HbA1c &lt;7% after 24 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients with reduction in HbA1c &gt;/= to 0.7% after 24 weeks</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event profile after 24 weeks of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1c at 24 weeks for patients with high baseline HbA1c vs low baseline HbA1c</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Vildagliptin 50 mg qd + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin 50 mg qd + pioglitazone 45 mg qd for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vildagliptin 50 mg bid + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin 50 mg bid + pioglitazone 45 mg qd for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vildagliptin placebo + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vildagliptin placebo + pioglitazone 45 mg qd for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin 50 mg tablets</description>
    <arm_group_label>Vildagliptin 50 mg bid + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_label>Vildagliptin 50 mg qd + pioglitazone 45 mg qd</arm_group_label>
    <other_name>LAF237</other_name>
    <other_name>Galvus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>pioglitazone 45 mg qd</description>
    <arm_group_label>Vildagliptin 50 mg bid + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_label>Vildagliptin 50 mg qd + pioglitazone 45 mg qd</arm_group_label>
    <arm_group_label>Vildagliptin placebo + pioglitazone 45 mg qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vildagliptin matching placebo</description>
    <arm_group_label>Vildagliptin placebo + pioglitazone 45 mg qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Blood glucose criteria must be met&#xD;
&#xD;
          -  Previously responded, as defined by the protocol, to treatment with pioglitazone or&#xD;
             rosiglitazone&#xD;
&#xD;
          -  Body mass index (BMI) in the range 22-45&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Evidence of serious cardiovascular complications&#xD;
&#xD;
          -  Evidence of serious diabetic complications&#xD;
&#xD;
          -  Laboratory value abnormalities as defined by the protocol&#xD;
&#xD;
          -  Known sensitivity to pioglitazone&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=2286</url>
    <description>Results for CLAF237A2304 from the Novartis Clinical Trials website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 21, 2004</study_first_submitted>
  <study_first_submitted_qc>December 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2004</study_first_posted>
  <disposition_first_submitted>December 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 28, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 1, 2013</disposition_first_posted>
  <last_update_submitted>December 11, 2020</last_update_submitted>
  <last_update_submitted_qc>December 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>vildagliptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

